An insight into the epitope-based peptide vaccine design strategy and studies against COVID-19

Topuzogullari M., Acar T., Pelit Arayıcı P., Uçar B., Uğurel E., Abamor E. Ş., ...Daha Fazla

TURKISH JOURNAL OF BIOLOGY, cilt.44, sa.3, ss.215-227, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 44 Sayı: 3
  • Basım Tarihi: 2020
  • Doi Numarası: 10.3906/biy-2006-1
  • Dergi Adı: TURKISH JOURNAL OF BIOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.215-227
  • Anahtar Kelimeler: SARS-CoV-2, COVID-19, epitope-based peptide vaccine design, adjuvant, immunoinformatics, HUMAN CORONAVIRUS, IMMUNE-RESPONSES, SPIKE PROTEIN, SARS, CELL, SEQUENCE, IMMUNIZATION, PREDICTION, ANTIBODIES, INFECTION
  • Yıldız Teknik Üniversitesi Adresli: Evet

Özet

SARS-CoV-2 is a new member of the coronavirus family and caused the pandemic of coronavirus disease 2019 (COVID-19) in 2020. It is crucial to design and produce an effective vaccine for the prevention of rapid transmission and possible deaths wcaused by the disease. Although intensive work and research are being carried out all over the world to develop a vaccine, an effective and approved formulation that can prevent the infection and limit the outbreak has not been announced yet. Among all types of vaccines, epitope-based peptide vaccines outshine with their low-cost production, easy modification in the structure, and safety. In this review, vaccine studies against COVID-19 have been summarized and detailed information about the epitope-based peptide vaccines against COVID-19 has been provided. We have not only compared the peptide vaccine with other types of vaccines but also presented comprehensive literature information about development steps for an effective and protective formulation to give an insight into on-going peptide vaccine studies against SARS-CoV-2.